1. Home
  2. REVB vs DCOY Comparison

REVB vs DCOY Comparison

Compare REVB & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.07

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$5.80

Market Cap

4.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REVB
DCOY
Founded
2020
N/A
Country
United States
United States
Employees
9
11
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REVB
DCOY
Price
$1.07
$5.80
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
39.6K
241.5K
Earning Date
05-07-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.53
52 Week High
$3.21
$13.51

Technical Indicators

Market Signals
Indicator
REVB
DCOY
Relative Strength Index (RSI) 54.39 45.15
Support Level $0.97 $5.08
Resistance Level $1.11 $6.47
Average True Range (ATR) 0.06 1.21
MACD 0.00 -0.14
Stochastic Oscillator 68.75 3.74

Price Performance

Historical Comparison
REVB
DCOY

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

Share on Social Networks: